Login to Your Account


GSK files MAA for gene therapy in ultra-rare disease ADA-SCID

By Cormac Sheridan
Staff Writer

Tuesday, May 5, 2015
DUBLIN – Bidding to become the second European firm to win a gene therapy approval, Glaxosmithkline plc filed a marketing authorization application with the EMA for GSK2696273, a treatment for severe combined immunodeficiency syndrome associated with ADA-SCID in patients for whom bone marrow transplants are not possible.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription